Crucell N.V. has been awarded contracts totaling more than $230 million for its Quinvaxem and Hepavax-Gene pediatric vaccines by supranational organizations. The contracts cover the next three years and the awarded amount will increase during those three years. Following the WHO prequalification in September 2006 the combination vaccine was made available to supranational purchasing organizations. These organizations are major customers for combination vaccines, which are used in large vacc...